




RealRate

PHARMACEUTICAL 2022

Unity Biotechnology Inc
Rank 336 of 471

UNITY
BIOTECHNOLOGY



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Unity Biotechnology Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Unity Biotechnology Inc compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 22% points. The greatest weakness of Unity Biotechnology Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 97% points.

The company's Economic Capital Ratio, given in the ranking table, is 208%, being 67% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	90,504
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,617
Liabilities, Non-Current	48,526
Other Assets	24,266
Other Compr. Net Income	-49
Other Expenses	3,177
Other Liabilities	0
Other Net Income	-883
Other Revenues	4,784
Property and Equipment	9,942
Research and Development	38,393
Selling, General and Administrative Expense	23,056

Output Variable	Value in 1000 USD
Assets	124,712
Liabilities	65,143
Expenses	64,626
Revenues	4,784
Stockholders Equity	59,569
Net Income	-60,725
Comprehensive Net Income	-60,750
BaseVar	130,098
ECR before LimitedLiability	73%
Economic Capital Ratio	208%